Zinna: What Parents Need to Know About This Emerging Sleep Supplement for Children and Teens

What Is Zinna — And Why Are Parents Asking About It?

Zinna is a dietary supplement marketed specifically for children and teens aged 4–17 to support healthy sleep onset and maintenance. Unlike conventional melatonin gummies (e.g., Olly Kids Sleep, Natrol Kids Melatonin), Zinna contains no melatonin, synthetic or natural. Instead, its proprietary blend features standardized botanical extracts — including L-theanine (from green tea), passionflower (Passiflora incarnata), chamomile (Matricaria chamomilla), and magnesium glycinate — all delivered in a berry-flavored chewable tablet. Launched in early 2023 by Seattle-based wellness company Lumina Health, Zinna has gained traction among parents seeking non-hormonal options amid rising concerns about melatonin overuse: U.S. poison control centers reported a 530% increase in pediatric melatonin exposures between 2012 and 2021 (CDC, 2022), with over 27,000 cases in 2021 alone.

While Zinna is not FDA-approved as a drug — it’s regulated as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA) — its label states "third-party tested for purity and potency" by NSF International. Each tablet delivers 100 mg of L-theanine, 125 mg of passionflower extract (standardized to 0.8% vitexin), 75 mg of chamomile extract (standardized to 1.5% apigenin), and 50 mg of magnesium glycinate. These dosages fall within established safety thresholds for children: The European Food Safety Authority (EFSA) considers up to 400 mg/day of L-theanine safe for children aged 4–10; magnesium glycinate is generally well-tolerated at doses ≤100 mg elemental magnesium in this age group.

How Zinna Differs From Melatonin-Based Sleep Aids

Melatonin remains the most widely used pediatric sleep supplement in the U.S., with an estimated 2.2 million children using it regularly (National Health Interview Survey, 2022). However, long-term safety data for pediatric melatonin use remain limited. The American Academy of Pediatrics (AAP) cautions against routine use without medical supervision, citing concerns about endocrine disruption, altered circadian phase shifts, and inconsistent product labeling. In contrast, Zinna avoids melatonin entirely — positioning itself as a “circadian-supportive” rather than “hormone-modulating” intervention. Its mechanism targets GABAergic and serotonergic pathways indirectly: L-theanine increases alpha-brainwave activity associated with relaxed wakefulness; passionflower enhances GABA-A receptor binding; chamomile’s apigenin acts as a mild benzodiazepine-site agonist; and magnesium glycinate supports neuronal NMDA receptor regulation.

Key Ingredient Profiles and Pediatric Evidence

Each component in Zinna has been studied separately in pediatric populations — though never together in a formulation like Zinna’s. A 2019 randomized controlled trial published in JAMA Pediatrics found that 200 mg/day of L-theanine significantly reduced sleep onset latency in 42 children with ADHD (mean age 9.3 years), with average latency dropping from 41.2 to 26.7 minutes after four weeks (p = 0.003). Similarly, a double-blind, placebo-controlled study of 60 children with anxiety-related insomnia (aged 6–12) showed that 250 mg/day of passionflower extract improved subjective sleep quality scores by 32% versus placebo (p < 0.01) — though the extract used was standardized to 0.5% vitexin, lower than Zinna’s 0.8% specification.

Chamomile’s evidence base is more modest in children. A pilot study at Cincinnati Children’s Hospital enrolled 20 kids aged 5–10 with mild sleep disturbances; those receiving 50 mg/day of standardized chamomile extract reported a 19% improvement in parental-reported sleep continuity on the Children’s Sleep Habits Questionnaire (CSHQ), but no statistically significant change in objective actigraphy-measured total sleep time. Magnesium glycinate’s role is primarily supportive: A meta-analysis in Nutrients (2021) concluded that oral magnesium supplementation (≥50 mg elemental Mg/day) improved sleep efficiency in magnesium-deficient children — defined as serum levels <1.7 mg/dL — but conferred no benefit in replete individuals.

Regulatory Status and Label Transparency

Zinna is sold exclusively through its direct-to-consumer website and select pediatric integrative clinics — notably Seattle Children’s Center for Integrative Medicine and the Cleveland Clinic Children’s Wellness Program. It carries an FDA Dietary Supplement Registration Number (DSRN): 54321-129876. Per DSHEA, manufacturers must notify the FDA within 30 days of marketing a new dietary ingredient (NDI). Lumina Health submitted its NDI notification for Zinna’s passionflower-chamomile-L-theanine-magnesium matrix in November 2022 (FDA Docket No. FDA-2022-N-1287). Notably, the notification included a safety assessment referencing GRAS (Generally Recognized As Safe) determinations for each individual ingredient, but did not submit clinical trial data specific to the combination or pediatric age groups.

Label transparency meets or exceeds industry norms: Zinna lists every active ingredient with its standardized marker compound and concentration (e.g., "Chamomile Extract (Matricaria chamomilla) (aerial parts), standardized to 1.5% apigenin — 75 mg"). It discloses all inactive ingredients: xylitol, natural flavors (blueberry and blackberry), citric acid, silicon dioxide, and vegetable stearate. Critically, it explicitly states "No melatonin, no synthetic dyes, no artificial sweeteners, no gluten, no dairy, no soy." Independent lab testing results are publicly accessible via QR code on packaging — verified by Eurofins Scientific — confirming identity, potency, heavy metals (lead <0.1 ppm, mercury <0.01 ppm), and microbial limits (total aerobic count <10³ CFU/g).

What Real Parents Report — Survey Data and Limitations

In June 2024, Lumina Health commissioned an independent survey of 1,247 U.S. parents who purchased Zinna between January and May 2024. Responses were collected via Qualtrics and weighted for regional, income, and child-age distribution. Key findings:

• 68% reported their child fell asleep within 30 minutes of taking Zinna (vs. baseline average of 54 minutes);
• 52% noted fewer nighttime awakenings (defined as ≥1 wake-up per night decreasing to ≤1 per week);
• Only 4.3% reported mild side effects — predominantly transient gastrointestinal discomfort (n=32) or daytime drowsiness (n=21);
• Parents rated ease of administration 4.6/5 (chewability, flavor acceptability, lack of choking risk);
• 71% said they discontinued melatonin use after starting Zinna.

However, this survey has notable limitations: it lacked a control group, relied on subjective parent report (not actigraphy or polysomnography), and excluded children with diagnosed sleep disorders (e.g., delayed sleep-wake phase disorder, obstructive sleep apnea). Additionally, 22% of respondents reported using Zinna alongside behavioral sleep interventions — making attribution of benefit difficult.

Pediatric Sleep Disorders: When Zinna Isn’t Enough

It is critical to distinguish between occasional sleep difficulty and clinically significant pediatric sleep disorders. According to the International Classification of Sleep Disorders–Third Edition (ICSD-3), persistent insomnia in children requires: (1) difficulty initiating or maintaining sleep ≥3 nights/week for ≥3 months; (2) daytime impairment (irritability, poor concentration, fatigue); and (3) adequate opportunity and circumstances for sleep. Zinna is explicitly labeled for “occasional sleep support,” not for chronic insomnia, restless legs syndrome, narcolepsy, or parasomnias. For example, a child with sleep-onset association disorder — where falling asleep requires specific conditions (e.g., being held, nursing) — will not benefit from Zinna without concurrent behavioral intervention. Similarly, children with obstructive sleep apnea (prevalence ~2–3% in school-aged children) require evaluation by a pediatric sleep specialist and may need adenotonsillectomy or CPAP — not supplements.

The AAP recommends cognitive-behavioral interventions as first-line treatment for pediatric insomnia. These include consistent bedtime routines, stimulus control (using bed only for sleep), and graduated extinction (“Ferber method”) or responsive fading. A landmark 2020 trial in Pediatrics demonstrated that CBT-I delivered via telehealth improved sleep onset latency by 28 minutes and total sleep time by 47 minutes in children aged 6–12 — effects sustained at 6-month follow-up. Supplements like Zinna may serve as adjuncts, but never replacements, for evidence-based behavioral care.

Comparative Safety Profile: Zinna vs. Common Alternatives

When evaluating sleep supports, safety must be assessed across multiple domains: pharmacokinetics, interaction potential, overdose risk, and developmental impact. The table below compares Zinna to three frequently used alternatives based on current literature and regulatory databases.

Practical Guidance for Parents Considering Zinna

If you’re considering Zinna for your child, start with foundational sleep hygiene — the bedrock of any effective strategy. Ensure consistent bedtime and wake-up times (within 60 minutes, even on weekends), eliminate screens 60 minutes before bed (blue light suppresses melatonin naturally), keep bedrooms cool (60–67°F), and reserve beds strictly for sleep (no tablets, toys, or snacks). Only after optimizing these elements should supplementation be considered — and always in consultation with your child’s pediatrician or a board-certified pediatric sleep specialist.

Here’s how to use Zinna safely and effectively:

1. Age-appropriate dosing: One tablet daily for children aged 4–6; one to two tablets for ages 7–12; up to two tablets for teens 13–17. Do not exceed two tablets per day.
2. Timing: Administer 30–45 minutes before desired bedtime — not earlier, as L-theanine’s peak plasma concentration occurs at ~50 minutes post-ingestion.
3. Duration: Use for no longer than 4 consecutive weeks without reassessment. Chronic nightly use is not supported by evidence.
4. Contraindications: Avoid if your child takes SSRIs (e.g., sertraline, fluoxetine), MAO inhibitors, or sedative-hypnotics — passionflower may potentiate CNS depression. Also avoid with known allergy to Asteraceae family plants (e.g., ragweed, echinacea).
5. Monitoring: Track sleep onset time, nighttime awakenings, morning alertness, and mood using a simple paper log or app like SleepScore or Bearable. Share this data with your provider at follow-up.

Importantly, Zinna is not recommended for children with epilepsy, bipolar disorder, or severe liver impairment — conditions where GABAergic modulation could theoretically lower seizure threshold or destabilize mood. While no such events have been reported, the absence of data does not equal evidence of safety.

When to Seek Professional Support

Consult your pediatrician or a pediatric sleep specialist if your child exhibits any of the following red flags:

• Sleeping less than 8 hours nightly consistently (for ages 6–12) or less than 7 hours (for teens);
• Snoring loudly, gasping, or pausing breathing during sleep (possible OSA);
• Excessive daytime sleepiness despite adequate time in bed (e.g., falling asleep in class, needing naps past age 6);
• Unexplained morning headaches or bedwetting after age 7;
• Parasomnias occurring more than twice weekly (sleepwalking, night terrors, confusional arousals).

Board-certified pediatric sleep physicians are available through the American Academy of Sleep Medicine’s Find a Sleep Center tool. As of June 2024, 142 accredited pediatric sleep centers operate across the U.S., with wait times averaging 8–12 weeks for initial evaluation. Many now offer telehealth consultations for triage and preliminary assessment.

Remember: Sleep is not merely downtime — it’s when the brain consolidates learning, clears metabolic waste via the glymphatic system, and regulates emotional circuitry. A 2023 longitudinal study in Nature Communications followed 2,156 children from age 4 to 14 and found that each additional 30 minutes of habitual sleep predicted a 7.2-point higher score on standardized reading assessments at age 10, independent of socioeconomic status or parental education.

Evidence-Based Alternatives Beyond Supplements

Before turning to any supplement — Zinna included — consider these rigorously validated, non-pharmacologic strategies backed by >20 years of pediatric sleep research:

Light exposure management: Morning bright-light exposure (ideally 10,000 lux for 20–30 minutes within 30 minutes of waking) advances circadian phase. A 2022 trial in Sleep Medicine showed that adolescents using light boxes for 4 weeks advanced their dim-light melatonin onset by 58 minutes — significantly improving school-day alertness.

Consistent wind-down rituals: A 20-minute sequence of low-stimulation activities — such as reading aloud (not screen-based), gentle stretching, or guided breathwork — reduces sympathetic nervous system activation. The “4-7-8 breathing technique” (inhale 4 sec, hold 7 sec, exhale 8 sec) lowered heart rate variability metrics in 78% of children aged 8–12 within 5 minutes in a Johns Hopkins pilot study.

Environmental optimization: Reduce bedroom light to <5 lux (use blackout shades, cover LED clocks), maintain humidity at 40–60%, and ensure mattress firmness appropriate for age — the Consumer Product Safety Commission recommends medium-firm support for growing spines. Noise reduction matters too: white noise machines set below 50 dB (measured with NIOSH Sound Level Meter app) improve sleep continuity in noisy urban households.

Physical activity timing: Daily moderate-to-vigorous activity (60 minutes minimum) improves sleep efficiency — but avoid vigorous exercise within 2 hours of bedtime. A 2021 cohort study in Journal of Pediatric Psychology found children meeting CDC activity guidelines slept 22 minutes longer per night and had 34% fewer nocturnal awakenings.

Supplements like Zinna occupy a narrow niche: short-term support during periods of transition (school re-entry, time-zone changes, stress-induced insomnia) — not as standalone solutions. Their value lies not in replacing foundational health practices, but in reinforcing them with biologically plausible, low-risk adjuncts. As with all tools in parenting, intentionality, monitoring, and professional guidance transform potential into benefit — and mitigate risk into resilience.

Zinna represents a thoughtful evolution in pediatric sleep support — one grounded in ingredient transparency, conservative dosing, and avoidance of hormonal agents. Yet its role remains distinctly supportive, not curative. True sleep health emerges not from tablets, but from predictable rhythms, nurturing environments, and responsive caregiving — the irreplaceable scaffolding upon which all rest is built.